Disease · MONDO_0005085
pterygium
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. pterygium. Diseases, record MONDO_0005085. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005085
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs7
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| RANIBIZUMAB | CHEMBL1201825 | Antibody | Phase 2/3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CYCLOSPORINE | CHEMBL160 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DIPYRIDAMOLE | CHEMBL932 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MITOMYCIN | CHEMBL105 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GATIFLOXACIN | CHEMBL31 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MOXIFLOXACIN | CHEMBL32 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets26
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| VEGFA | Vascular endothelial growth factor A, long form | 2 | Vascular endothelial growth factor A inhibitor | Phase 3 | https://conductscience.org/library/genes/7422 | Drugs and targets |
| PDE10A | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 2 | https://conductscience.org/library/genes/10846 | Drugs and targets |
| PDE1A | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 2 | https://conductscience.org/library/genes/5136 | Drugs and targets |
| PDE1B | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 2 | https://conductscience.org/library/genes/5153 | Drugs and targets |
| PDE1C | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 2 | https://conductscience.org/library/genes/5137 | Drugs and targets |
| PDE2A | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 2 | https://conductscience.org/library/genes/5138 | Drugs and targets |
| PDE3A | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 2 | https://conductscience.org/library/genes/5139 | Drugs and targets |
| PDE3B | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 2 | https://conductscience.org/library/genes/5140 | Drugs and targets |
| PDE4A | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 2 | https://conductscience.org/library/genes/5141 | Drugs and targets |
| PDE4B | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 2 | https://conductscience.org/library/genes/5142 | Drugs and targets |
1 to 10 of 26
See all 26 targetsTrials14
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01109056 | Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium | Phase 2 | 115 | 2012-06-25 | Pterygium | CYCLOSPORINE | Its record names the disease | ClinicalTrials.gov |
| NCT00592176 | The Effect of Bevacizumab (Avastin) on Pterygium | Phase 2 | 5 | 2012-06-25 | Pterygium | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01380678 | Intralesional Bevacizumab Injection on Primary Pterygium | Phase 3 | 206 | Pterygium, Inflammation | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01288404 | Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium | Not applicable | 80 | Pterygium of the Conjunctiva and Cornea | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05627947 | Comparison Between Topical Mitomycin C and Cyclosporine | Phase 1 | 57 | Pterygium | MITOMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04878835 | Effects of Ranibizumab in Primary Pterygium Surgery | Phase 1 | 52 | Patients With Primary Nasal Pterygium | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01686529 | Bevacizumab for Primary Pterygium Treatment | Phase 1 | 49 | Pterygium | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00892918 | Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision | Not applicable | 40 | Primary Pterygium | GATIFLOXACIN, MOXIFLOXACIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02782260 | Assessment of the Efficacy of Ocular Dipyridamole in the Treatment of Dry Eye Symptomology in Subjects With Pterygium | Phase 2 | 40 | Dry Eye Syndromes, Pterygium | DIPYRIDAMOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT02007174 | Bevacizumab Injection for Recurrent Pterygium | 38 | Recurrent Pterygium | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 14
See all 14 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Cyclosporine Ophthalmic Emulsion 0.05% vs Vehicle: serious adverse events | 1 of 56 | 1 of 58 | 114 | NCT01109056 | Trial comparisons |
| Cyclosporine Ophthalmic Emulsion 0.05% vs Vehicle: Number of Pterygium Hyperemia Responders at Week 16 | 6 of 56 | 8 of 57 | 113 | NCT01109056 | Trial comparisons |
Papers from its trials22
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005085
GET https://conductscience.org/api/diseases/v1/MONDO_0005085/targets?page=2